keyword
MENU ▼
Read by QxMD icon Read
search

HIPEC and Gastric

keyword
https://www.readbyqxmd.com/read/29203985/setting-up-of-the-indian-hipec-registry-a-registry-for-indian-patients-with-peritoneal-surface-malignancies
#1
Aditi Bhatt, Sanket Mehta, Ramakrishnan As, Pankaj Pande, Firoz Rajan, Ashvin Rangole, Avanish Saklani, Kayomarz Sethna, Shivendra Singh, Shabber Zaveri, K S Gopinath
There are various registries for patients with peritoneal metastases (PM) that aid pooling of data and generate evidence that dictates current clinical practice. This manuscript describes the setting up of the Indian HIPEC registry that was set up with a similar goal by a group of Indian surgeons. This is a registry for patients with PM treated with CRS and HIPEC in India. It also acts as a database for storing treatment-related information. Patients with PM from colorectal ovarian, gastric, appendiceal tumors, and other rare peritoneal tumors/metastases from rare tumors are enrolled in the registry...
December 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29183538/laparoscopic-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-carcinomatosisfrom-gastric-cancer-its-beneficial-effects-on-reduction-and-exact-evaluation-of-the-peritoneal-cancer-index
#2
Kazuyoshi Takeshita, Yang Liu, Haruaki Ishibashi, Yutaka Yonemura
We assessed whether the laparoscopic hyperthermic intraperitoneal chemotherapy (L-HIPEC) + neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) could reduce the peritoneal cancer index (PCI; which is defined by Sugerbaker) and improve the possibility to obtain a complete cytoreductive surgery (CRS with peritonectomy; basically according to the Sugerbaker's procedure). After L-HIPEC + NIPS, the PCI score was decreased in 89.5 per cent of patients, and the average score was significantly reduced. The average PCI reduction of improved PCI cases was 10...
November 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/29135095/does-upfront-therapy-with-cytoreductive-surgery-and-hipec-confer-a-survival-benefit-in-patients-with-synchronous-gastric-peritoneal-carcinomatosis-when-compared-with-patients-with-metachronous-gastric-peritoneal-carcinomatosis
#3
Nikolaos Kopanakis, Elias Efstathiou, Dimitrios Sarris, John Spiliotis
Gastric cancer (GC) remains the second leading cause of cancer death worldwide, accounting for 8% of the total cases and 10% of total deaths in 2008. Surgery remains the curative treatment option for GC and the main reason for treatment failure is peritoneal recurrence which, according to the literature, occurs in 40-60% of the cases, despite extensive surgery including D2 lymph node dissection. The hyperthermic intraperitoneal chemotherapy (HIPEC) technique is increasingly used in the treatment of primary and digestive peritoneal carcinomatosis (PC), in association with cytoreductive surgery (CRS)...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28855982/peritoneal-metastases-of-rare-carcinomas-treated-with-cytoreductive-surgery-and-hipec-a-single-center-case-series
#4
Andreas Brandl, Christina Barbara Zielinski, Wieland Raue, Johann Pratschke, Beate Rau
INTRODUCTION: In selected cases, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for patients suffering from peritoneal metastases from colorectal, ovarian, gastric or appendiceal origin. The effectiveness of this extensive has not been elucidated within other rare diseases by now. METHODS: We conducted a retrospective analysis of patients treated with CRS for peritoneal carcinomatosis during the period between July 2010 and September 2015...
October 2017: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/28808875/ssat-state-of-the-art-conference-current-surgical-management-of-gastric-tumors
#5
Jeffrey A Norton, Teresa Kim, Joseph Kim, Martin D McCarter, Kaitlyn J Kelly, Joyce Wong, Jason K Sicklick
INTRODUCTION: The current era of gastric surgery is marked by low morbidity and mortality rates, innovative strategies to approach resections with a minimally invasive fashion or hyperthermic intraperitoneal chemotherapy (HIPEC), as well as improved understanding of the biology of sporadic and hereditary stromal, neuroendocrine, and epithelial malignancies. METHODS: In 2017, the Society for Surgery of the Alimentary Tract convened a State-of-the-Art Conference on Current Surgical Management of Gastric Tumors with both international experts and emerging leaders in the field of gastric surgery...
August 14, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28799004/phase-ii-trial-of-laparoscopic-hyperthermic-intraperitoneal-chemoperfusion-for-peritoneal-carcinomatosis-or-positive-peritoneal-cytology-in-patients-with-gastric-adenocarcinoma
#6
Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Linus Ho, Keith Fournier, Richard Royal, Paul Mansfield, Jaffer Ajani
PURPOSE: The aim of this phase II study was to perform neoadjuvant hyperthermic intraperitoneal chemoperfusion (HIPEC) via a minimally invasive approach without cytoreduction for patients with gastric cancer and positive peritoneal cytology or low-volume peritoneal carcinomatosis. METHODS: Patients with gastric or gastroesophageal adenocarcinoma and positive peritoneal cytology or radiologically occult peritoneal carcinomatosis after systemic chemotherapy received laparoscopic HIPEC with mitomycin C 30 mg and cisplatin 200 mg...
October 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28743181/feasibility-and-safety-of-hyperthermic-intraperitoneal-chemotherapy-using-5-fluorouracil-combined-with-cisplatin-and-mitomycin-c-in-patients-undergoing-gastrectomy-for-advanced-gastric-cancer
#7
Satoshi Murata, Hiroshi Yamamoto, Hiroyuki Naitoh, Tsuyoshi Yamaguchi, Sachiko Kaida, Tomoharu Shimizu, Hisanori Shiomi, Shigeyuki Naka, Tohru Tani, Masaji Tani
BACKGROUND AND OBJECTIVES: We conducted a dose-finding study for 5-fluorouracil (5-FU) administered with cisplatin (CDDP) and mitomycin C (MMC) to find an improved regimen for hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer (GC). METHODS: The appropriate HIPEC regimen previously determined in vitro was 5-FU (200 µg/mL), MMC (2 µg/mL), and CDDP (10 µg/mL) at hyperthermic conditions (42°C) for 30 min. This was a clinical study to determine the recommended dose of 5-FU in combination with MMC and CDDP at 42°C for 30 min and to evaluate HIPEC safety in patients at high risk of developing peritoneal metastases following GC surgery...
July 25, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28736644/overall-and-disease-free-survival-in-patients-treated-with-crs-hipec-with-cisplatin-and-paclitaxel-for-gastric-cancer-with-peritoneal-carcinomatosis
#8
Paola Fugazzola, Federico Coccolini, Giulia Montori, Marco Ceresoli, Paolo Baggi, Antonio Costanzo, Matteo Tomasoni, Francesco Gregis, Silvia Nozza, Luca Ansaloni
BACKGROUND: Our experience regarding cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was reviewed in terms of overall survival (OS) and disease-free survival (DFS) in patients with synchronous peritoneal carcinomatosis (SPC) and metachronous peritoneal carcinomatosis (MPC) from gastric cancer (GC). METHODS: An analysis of prospectively collected data about patients who underwent CRS and HIPEC from July 2011 to July 2016 was carried out...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28705789/treatment-of-peritoneal-dissemination-in-stomach-cancer-patients-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-rationale-and-design-of-the-periscope-study
#9
Rosa T van der Kaaij, Hidde Jw Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan Hm Schellens, Arend Gj Aalbers, Alwin Dr Huitema, Catherijne Aj Knibbe, Djamila Boerma, Marinus J Wiezer, Bert van Ramshorst, Johanna W van Sandick
BACKGROUND: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; median survival is 3 to 4 months. Palliative systemic chemotherapy is currently the only treatment available in the Netherlands. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has an established role in the treatment of peritoneal carcinomatosis originating from colorectal cancer, appendiceal cancer, and pseudomyxoma peritonei; its role in gastric cancer is uncertain. Currently, there is no consensus on the choice of chemotherapeutic agents used in HIPEC for gastric cancer...
July 13, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28679331/predictive-value-of-peritoneal-cancer-index-for-survival-in-patients-with-mucinous-peritoneal-malignancies-treated-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-a-single-centre-experience
#10
Andreas Brandl, Sascha Weiss, Moritz von Winterfeld, Alexander Krannich, Mathilde Feist, Johann Pratschke, Wieland Raue, Beate Rau
OBJECTIVES: This study investigated the correlation between the peritoneal carcinomatosis index (PCI) and patient outcome depending on the tumour type. BACKGROUND: Peritoneal surface malignancy (PSM) treatment depends on tumour type. Mucinous PSM (m-PSM) is associated with a better prognosis than non-mucinous PSM (nm-PSM). The PCI's predictive ability has not yet been evaluated. METHODS: We analysed 123 patients with PSM treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) between 2008 and 2015...
July 26, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28658135/experiences-with-cytoreduction-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-in-taiwan
#11
Mao-Chih Hsieh, Chang-Yun Lu, Wei-Wen Chang, Szu-Yuan Wu, Ping-Kun Hsiao, Tse-Jia Liu
Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC.Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases of laparoscopic or prophylactic HIPEC. The cases were categorized according to whether they were treated before 2012 (Period 1: 80 cases) or after 2012 (Period 2: 84 cases).The rates of surgical morbidity were 46...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28643069/lessons-learned-from-a-phase-ii-clinical-trial-of-laparoscopic-hipec-for-gastric-cancer
#12
Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Keith Fournier, Richard Royal, Paul Mansfield, Jaffer Ajani
BACKGROUND: Over the last two decades, intraperitoneal chemotherapy has been found to have activity for select subgroups of patients with carcinomatosis from colon, ovarian, appendiceal, and recently, gastric origins. However, there is little data to support an aggressive surgical approach of cytoreduction (debulking) and hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) for patients with gastric cancer and positive cytology or carcinomatosis. The morbidity and mortality rates of cytoreduction and HIPEC, in combination with gastrectomy, are significant and the survival rates of this approach may not extend beyond that of treatment with systemic chemotherapy...
June 22, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28540827/complete-cytoreductive-surgery-plus-hipec-for-peritoneal-metastases-from-unusual-cancer-sites-of-origin-results-from-a-worldwide-analysis-issue-of-the-peritoneal-surface-oncology-group-international-psogi
#13
Diane Goéré, Guillaume Passot, Maximiliano Gelli, Edward A Levine, David L Bartlett, Paul H Sugarbaker, Olivier Glehen
AIM: The aim of this study was to assess the outcomes of patients operated on for peritoneal metastases from unusual cancer sites of origin, meaning apart from peritoneal metastases (PM) from colorectal, gastric and epithelial ovarian carcinomas, pseudomyxoma peritonei and mesothelioma. PATIENTS AND METHODS: A questionnaire concerning patients treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for PM arising from unusual cancer sites of origin was sent to all centres, which routinely performed HIPEC, through the Peritoneal Surface Oncology Group International and the RENAPE network...
August 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540826/drugs-doses-and-durations-of-intraperitoneal-chemotherapy-standardising-hipec-and-epic-for-colorectal-appendiceal-gastric-ovarian-peritoneal-surface-malignancies-and-peritoneal-mesothelioma
#14
Lieselotte Lemoine, Paul Sugarbaker, Kurt Van der Speeten
Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynaecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardisation regarding the CRS, we are still lacking a much-needed standardisation amongst the various IP chemotherapy treatment modalities used today in clinical practice...
August 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28507577/peritoneal-lavage-examination-as-a-prognostic-tool-in-cases-of-gastric-cancer
#15
David Hoskovec, Jozef Varga, Petr Dytrych, Ellen Konecna, Jan Matek
INTRODUCTION: Peritoneal tumor seeding is a common form of recurrence after gastric cancer surgery. The finding of free tumor cells and/or elevation of tumor markers in the peritoneal fluid could predict intraperitoneal tumor recurrence. The results of these examination can be used for indication of aggressive treatment modalities such as hyperthermic intraperitoneal chemotherapy (HIPEC). MATERIAL AND METHODS: We have operated on 105 patients suffering from gastric cancer...
April 1, 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28501134/factors-associated-with-palliative-care-use-in-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#16
Rachel S Morris, Faiz Gani, Abdulrahman Y Hammad, Wendy Peltier, T Clark Gamblin, Kiran K Turaga, Fabian M Johnston
BACKGROUND: Peritoneal carcinomatosis represents widespread metastatic disease throughout the abdomen and/or pelvis. Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) improves the overall survival compared to standard therapy alone. The role palliative care (PC) plays however, remains poorly studied among these patients. METHODS: Patients who had previously undergone HIPEC and who underwent an inpatient admission from 7/1/2013 to 6/30/2014 were identified to determine which patients were referred for inpatient or outpatient palliative consultation...
May 1, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28456089/the-30-year-experience-a-meta-analysis-of-randomised-and-high-quality-non-randomised-studies-of-hyperthermic-intraperitoneal-chemotherapy%C3%A2-in-the-treatment-of-gastric-cancer
#17
REVIEW
Jacopo Desiderio, Joseph Chao, Laleh Melstrom, Susanne Warner, Federico Tozzi, Yuman Fong, Amilcare Parisi, Yanghee Woo
IMPORTANCE: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used within various multimodality strategies for the prevention and treatment of gastric cancer peritoneal carcinomatosis. OBJECTIVE: To systematically evaluate the role of HIPEC in gastric cancer and clarify its effectiveness at different stages of peritoneal disease progression. DATA SOURCES: Medline and Embase databases between January 1, 1985 and June 1, 2016. STUDY SELECTION: Randomised control trials and high-quality non-randomised control trials selected on a validated tool (methodological index for non-randomised studies) comparing HIPEC and standard oncological management for the treatment of advanced stage gastric cancer with and without peritoneal carcinomatosis were considered...
July 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28415645/peritoneal-carcinomatosis-limits-of-diagnosis-and-the-case-for-liquid-biopsy
#18
REVIEW
James R W McMullen, Matthew Selleck, Nathan R Wall, Maheswari Senthil
Peritoneal Carcinomatosis (PC) is a late stage manifestation of several gastrointestinal malignancies including appendiceal, colorectal, and gastric cancer. In PC, tumors metastasize to and deposit on the peritoneal surface and often leave patients with only palliative treatment options. For colorectal PC, median survival is approximately five months, and palliative systemic therapy is able to extend this to approximately 12 months. However, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) with a curative intent is possible in some patients with limited tumor burden...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28373757/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-treatment-of-gastric-cancer-with-peritoneal-carcinomatosis
#19
Lynne M Ellison, Yangao Man, Alexander Stojadinovic, Hongwu Xin, Itzhak Avital
Although gastric cancer with peritoneal carcinomatosis is associated with poor prognosis and is generally treated with palliative systemic therapy, recent studies have shown that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may prove to be an efficacious treatment option. In addition to reviewing the natural history of gastric cancer with peritoneal carcinomatosis, this mini-review examines literature on the efficacy of CRS and HIPEC as compared to chemotherapy and surgical options...
February 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/28187769/gastric-perforation-following-cytoreductive-surgery-and-perioperative-intraperitoneal-chemotherapy-a-case-series-of-six
#20
Lee S Kyang, Nayef A Alzahrani, Jing Zhao, David L Morris
BACKGROUND: Incidence of gastric perforation following cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) is not widely reported. METHODS: Suitable patients were identified from our database of 1028 procedures. Relevant information was then gathered via medical records and operation reports for these patients. RESULTS: Six patients suffered early postoperative gastric perforation following the procedure (0.58%), all of whom received heated intraoperative intraperitoneal chemotherapy (HIPEC)...
February 10, 2017: World Journal of Surgical Oncology
keyword
keyword
98794
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"